Skip to main content
. 2023 Oct 28;14:6895. doi: 10.1038/s41467-023-42585-9

Fig. 6. Clinical actionability of MSK-IMPACT Heme results.

Fig. 6

a Percentage of samples across all tumor types that harbor a mutation considered clinically actionable according to the OncoKB therapeutic levels of evidence. b Distribution of IPSS-M algorithm calculated scores and risk categories identified in the 101 cases in the MSK-IMPACT Heme cohort. In the box plots, the central line represents the median; the box corresponds to 25–75% quartiles; the upper whisker extends to the largest value no farther than 1.5× IQR; and the lower whisker extends from the 25% quartile to the smallest value no farther than 1.5× IQR. c The number of patients in the MSK-IMPACT Heme MDS cohort with the given genomic alteration and their stratification into IPSS-M risk categories. Source data are provided as a Source Data file.